{"id":28821,"date":"2026-08-12T12:23:36","date_gmt":"2026-08-12T04:23:36","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=28821"},"modified":"2026-08-18T11:29:21","modified_gmt":"2026-08-18T03:29:21","slug":"snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/","title":{"rendered":"Snapshot week 34\/2026<br> Anti-TBE virus effects of cepharanthine"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">Tang, W.-D. and Zhao, L.-J.<br>Cepharanthine inhibits tick-borne encephalitis virus infection through modulation of the stress and inflammation response <em>Int. J. Mol. Med.<\/em> 2026, 58:261, doi: 10.3892\/ijmm.2026.5932<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There is currently no specific antiviral drug available to treat TBE virus infection. Various potential anti-TBE virus agents have been discussed previously (see, e.g., <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-36-2024inhibition-of-tbe-virus-replication-by-the-tetracycline-derivative-minocycline\/\" data-type=\"link\" data-id=\"https:\/\/tbenews.com\/tbe\/snapshot-week-36-2024inhibition-of-tbe-virus-replication-by-the-tetracycline-derivative-minocycline\/\">Snapshot week 36\/2024<\/a>, <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-32-2023-assessing-ribavirin-as-an-anti-tbe-virus-drug\/\" data-type=\"link\" data-id=\"https:\/\/tbenews.com\/tbe\/snapshot-week-32-2023-assessing-ribavirin-as-an-anti-tbe-virus-drug\/\">Snapshot week 32\/2023<\/a>, and <a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/\" data-type=\"link\" data-id=\"https:\/\/tbenews.com\/tbe\/snapshot-week-5-2021treatment-of-a-tbe-patient-with-an-antiviral-drug\/\">Snapshot week 5\/2021<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A Chinese research team assessed the antiviral potential of cepharanthine against the TBE virus and investigated its underlying mechanisms. Cepharanthine is a bisbenzylisoquinoline alkaloid derived from the plant <em>Stephania cepharantha<\/em>. It exhibits multiple pharmacological properties, including antioxidative, anti-inflammatory, immunoregulatory, anticancer, antiviral, and antiparasitic activities. The drug has been used in Japan since the 1950s to treat various acute and chronic diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In human lung adenocarcinoma A549 cells and human neuroblastoma SH-SY5Y cells, cepharanthine inhibited TBE virus RNA replication, viral protein expression, and virus propagation. In co-treatment and pre-treatment experiments, inhibition of viral RNA replication was concentration-dependent.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In TBE virus-infected A549 cells, the production of the inflammatory cytokines TNF-\u03b1, IL-1\u03b2, and IL-11 was reduced by cepharanthine treatment. Effects on IL-11 production were also observed in infected SH-SY5Y cells, although these varied according to treatment conditions and cepharanthine concentration.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In infected A549 and SH-SY5Y cells, mRNA levels of C\/EBP homologous protein (CHOP), a major component of endoplasmic reticulum (ER) stress-induced apoptosis that is also involved in microbial infection processes, were decreased following co-treatment or pre-treatment with cepharanthine. CHOP protein expression was also downregulated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Phosphorylation of eukaryotic initiation factor 2\u03b1 (eIF2\u03b1) was enhanced during TBE virus infection following cepharanthine treatment. The authors suggest that modulation of ER stress and the inflammatory response may contribute to the observed antiviral effects, although the precise molecular mechanisms remain to be established.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In summary, cepharanthine showed notable anti-TBE virus activity in vitro, reducing viral replication, viral protein expression, and infectious virus production while modulating cellular stress and inflammatory responses. The findings support further investigation of cepharanthine as a potential antiviral agent against the TBE virus. Further in vivo studies, including animal studies, are warranted.<\/p>\n\n\n\n<div style=\"background:#f4f4f4; border:1px solid #d0d0d0; border-left:3px solid #9a9a9a; border-radius:6px; padding:18px 18px 16px 18px; margin:20px 0; color:#333; font-family:Arial, sans-serif; font-size:14px; line-height:1.7;\">\n\n    <div style=\"font-weight:bold; font-size:16px; margin-bottom:14px;\">\n        Editor\u2018s comment\n    <\/div>\n\n    <p style=\"margin:0 0 12px 0;\">\n        Considering that TBE is a relatively rare disease, it is generally assumed that developing and licensing a new antiviral drug specifically for its treatment would be difficult to justify commercially. Cepharanthine, however, may deserve further consideration.\n    <\/p>\n\n    <p style=\"margin:0 0 12px 0;\">\n        As an already licensed drug that has been used in Japan for several indications and has an established tolerability and safety profile, it could potentially be evaluated for compassionate use in TBE. The challenge is how such experience could be gained responsibly.\n    <\/p>\n\n    <p style=\"margin:0 0 12px 0;\">\n        Clinicians may understandably be reluctant to use an experimental treatment in patients with mild or moderate TBE, while introducing it only in very severe cases may make it difficult to assess efficacy and could come too late in the course of disease.\n    <\/p>\n\n    <p style=\"margin:0;\">\n        This raises a broader question: <em>should hospitals and clinical researchers with substantial experience in treating TBE patients come together to develop a structured pathway for evaluating drugs such as cepharanthine?<\/em>\n    <\/p>\n\n    <p style=\"margin:0;\">\n        A jointly agreed protocol defining patient selection, timing of treatment, clinical endpoints, safety monitoring, and systematic data collection could provide a more meaningful basis for assessing whether compassionate use is warranted\u2014and whether further clinical investigation should follow.\n    <\/p>\n\n<\/div>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Tang, W.-D. and Zhao, L.-J.Cepharanthine inhibits tick-borne encephalitis virus infection through modulation of the stress and inflammation response Int. J. Mol. Med. 2026, 58:261, doi: 10.3892\/ijmm.2026.5932 There is currently no specific antiviral drug available to treat TBE virus infection. Various potential anti-TBE virus agents have been discussed previously (see, e.g., Snapshot week 36\/2024, Snapshot week 32\/2023, and Snapshot week 5\/2021). A Chinese research team assessed the antiviral potential of cepharanthine against the TBE virus and investigated its underlying mechanisms. Cepharanthine is a bisbenzylisoquinoline alkaloid derived from the plant Stephania cepharantha. It exhibits multiple pharmacological properties, including antioxidative, anti-inflammatory, immunoregulatory, anticancer, antiviral, and antiparasitic activities. The drug has been used in Japan since the 1950s to treat various acute and chronic diseases. In human lung adenocarcinoma A549 cells and human neuroblastoma SH-SY5Y cells, cepharanthine inhibited TBE virus RNA replication, viral protein expression, and virus propagation. In co-treatment and pre-treatment experiments, inhibition of viral RNA replication was concentration-dependent. In TBE virus-infected A549 cells, the production of the inflammatory cytokines TNF-\u03b1, IL-1\u03b2, and IL-11 was reduced by cepharanthine treatment. Effects on IL-11 production were also observed in infected SH-SY5Y cells, although these varied according to treatment conditions and cepharanthine concentration. In infected A549 and SH-SY5Y cells, mRNA levels of C\/EBP homologous protein (CHOP), a major component of endoplasmic reticulum (ER) stress-induced apoptosis that is also involved in microbial infection processes, were decreased following co-treatment or pre-treatment with cepharanthine. CHOP protein expression was also downregulated. Phosphorylation of eukaryotic initiation factor 2\u03b1 (eIF2\u03b1) was enhanced during TBE virus infection following cepharanthine treatment. The authors suggest that modulation of ER stress and the inflammatory response may contribute to the observed antiviral effects, although the precise molecular mechanisms remain to be established. In summary, cepharanthine showed notable anti-TBE virus activity in vitro, reducing viral replication, viral protein expression, and infectious virus production while modulating cellular stress and inflammatory responses. The findings support further investigation of cepharanthine as a potential antiviral agent against the TBE virus. Further in vivo studies, including animal studies, are warranted. Editor\u2018s comment Considering that TBE is a relatively rare disease, it is generally assumed that developing and licensing a new antiviral drug specifically for its treatment would be difficult to justify commercially. Cepharanthine, however, may deserve further consideration. As an already licensed drug that has been used in Japan for several indications and has an established tolerability and safety profile, it could potentially be evaluated for compassionate use in TBE. The challenge is how such experience could be gained responsibly. Clinicians may understandably be reluctant to use an experimental treatment in patients with mild or moderate TBE, while introducing it only in very severe cases may make it difficult to assess efficacy and could come too late in the course of disease. This raises a broader question: should hospitals and clinical researchers with substantial experience in treating TBE patients come together to develop a structured pathway for evaluating drugs such as cepharanthine? A jointly agreed protocol defining patient selection, timing of treatment, clinical endpoints, safety monitoring, and systematic data collection could provide a more meaningful basis for assessing whether compassionate use is warranted\u2014and whether further clinical investigation should follow.<\/p>\n","protected":false},"author":94681,"featured_media":20968,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18,1324],"tags":[1484,1028,1485,650,1486,1030],"coauthors":[1108],"class_list":["post-28821","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","category-snapshot-2026","tag-alkaloid","tag-antiviral-drug","tag-cepharanthine","tag-cytokines","tag-in-vitro-studies","tag-inflammation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine - TBE Book<\/title>\n<meta name=\"description\" content=\"A new study finds that cepharanthine inhibits TBE virus replication in vitro, highlighting its potential as an antiviral candidate for tick-borne encephalitis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine - TBE Book\" \/>\n<meta property=\"og:description\" content=\"A new study finds that cepharanthine inhibits TBE virus replication in vitro, highlighting its potential as an antiviral candidate for tick-borne encephalitis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T04:23:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-18T03:29:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"logesan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"logesan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/\"},\"author\":{\"name\":\"logesan\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/eea00490409f8d848a28485d0f68fac3\"},\"headline\":\"Snapshot week 34\\\/2026 Anti-TBE virus effects of cepharanthine\",\"datePublished\":\"2026-08-12T04:23:36+00:00\",\"dateModified\":\"2026-08-18T03:29:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/\"},\"wordCount\":537,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"keywords\":[\"alkaloid\",\"antiviral drug\",\"cepharanthine\",\"cytokines\",\"in vitro studies\",\"inflammation\"],\"articleSection\":[\"Snapshot\",\"Snapshot 2026\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/\",\"name\":\"Snapshot week 34\\\/2026 Anti-TBE virus effects of cepharanthine - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2026-08-12T04:23:36+00:00\",\"dateModified\":\"2026-08-18T03:29:21+00:00\",\"description\":\"A new study finds that cepharanthine inhibits TBE virus replication in vitro, highlighting its potential as an antiviral candidate for tick-borne encephalitis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 34\\\/2026 Anti-TBE virus effects of cepharanthine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/eea00490409f8d848a28485d0f68fac3\",\"name\":\"logesan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g23fd037fb0950eb6606e07f441b58289\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g\",\"caption\":\"logesan\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/logesan\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine - TBE Book","description":"A new study finds that cepharanthine inhibits TBE virus replication in vitro, highlighting its potential as an antiviral candidate for tick-borne encephalitis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine - TBE Book","og_description":"A new study finds that cepharanthine inhibits TBE virus replication in vitro, highlighting its potential as an antiviral candidate for tick-borne encephalitis.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/","og_site_name":"TBE Book","article_published_time":"2026-08-12T04:23:36+00:00","article_modified_time":"2026-08-18T03:29:21+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"logesan","twitter_card":"summary_large_image","twitter_misc":{"Written by":"logesan","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/"},"author":{"name":"logesan","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/eea00490409f8d848a28485d0f68fac3"},"headline":"Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine","datePublished":"2026-08-12T04:23:36+00:00","dateModified":"2026-08-18T03:29:21+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/"},"wordCount":537,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","keywords":["alkaloid","antiviral drug","cepharanthine","cytokines","in vitro studies","inflammation"],"articleSection":["Snapshot","Snapshot 2026"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/","name":"Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","datePublished":"2026-08-12T04:23:36+00:00","dateModified":"2026-08-18T03:29:21+00:00","description":"A new study finds that cepharanthine inhibits TBE virus replication in vitro, highlighting its potential as an antiviral candidate for tick-borne encephalitis.","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2026-anti-tbe-virus-effects-of-cepharanthine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 34\/2026 Anti-TBE virus effects of cepharanthine"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/eea00490409f8d848a28485d0f68fac3","name":"logesan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g23fd037fb0950eb6606e07f441b58289","url":"https:\/\/secure.gravatar.com\/avatar\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g","caption":"logesan"},"url":"https:\/\/tbenews.com\/tbe\/author\/logesan\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/28821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/94681"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=28821"}],"version-history":[{"count":8,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/28821\/revisions"}],"predecessor-version":[{"id":28832,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/28821\/revisions\/28832"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/20968"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=28821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=28821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=28821"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=28821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}